Keros Therapeutics, Inc.
KROS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001664710
In the last 90 days, Keros Therapeutics, Inc. insiders filed 2 open-market purchases and 4 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $213.7M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $20.9K in total
- 2
- Insider sellsLast 90 days, $101.1K in total
- 4
- 13F holdersQ2 2026, −16 vs. previous quarter
- 132
- 13F valueReported value at the end of Q2 2026
- $213.7M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding KROS, Q2 2026
No superinvestor reported holding KROS at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Keros Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2026 (view filing)4:10 PM ET | Aug 18 | 2 days | Tanini AnnitaCorp. Controller & VP, Finance | SSale | −1.22K | $10.29 | −$12.6K | −2.6%45.1K after | |
| Aug 20, 2026 (view filing)4:10 PM ET | Aug 18 | 2 days | Lerner Lorena RaquelChief Scientific Officer | SSale | −3.57K | $10.29 | −$36.7K | −11.5%27.6K after | |
| Aug 20, 2026 (view filing)4:10 PM ET | Aug 18 | 2 days | Cho EstherChief Legal Officer | SSale | −4.49K | $10.29 | −$46.2K | −11.1%35.8K after | |
| Aug 20, 2026 (view filing)4:10 PM ET | Aug 18 | 2 days | Newton Charles W.Director | SSale | −551 | $10.30 | −$5.68K | −4.4%12.1K after | 10b5-1 |
| Aug 19, 2026 (view filing)4:10 PM ET | Aug 17 | 2 days | Bienaime Jean JacquesDirector | PPurchase | +1.00K | $10.27 | +$10.3K | +5.4%19.6K after | 10b5-1 |
| Jul 17, 2026 (view filing)4:10 PM ET | Jul 15 | 2 days | Bienaime Jean JacquesDirector | PPurchase | +1.00K | $10.61 | +$10.6K | +5.7%18.6K after | 10b5-1 |
| Jun 17, 2026 (view filing) | Jun 15 | 2 days | Bienaime Jean JacquesDirector | PPurchase | +1.00K | $10.19 | +$10.2K | +6.0%17.6K after | 10b5-1 |
| Jun 15, 2026 (view filing) | Jun 11 | 4 days | Newton Charles W.Director | SSale | −550 | $10.04 | −$5.52K | −4.2%12.7K after | 10b5-1 |
| Jun 8, 2026 (view filing) | Jun 4 | 4 days | Knowles JuliusDirector | SSale | −2.63K | $10.73 | −$28.2K | −19.3%11.0K after | 10b5-1 |
| Jun 8, 2026 (view filing) | Jun 4 | 4 days | Farzan NimaDirector | SSale | −2.63K | $10.73 | −$28.2K | −21.2%9.77K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Keros Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 2,820,838 | $30.2M | 0.91% | +1,460,419+107.4% | Added |
| BlackRock, Inc. | 2,794,217 | $29.9M | 0.00% | +382,424+15.9% | Added |
| AQR Capital Management LLC | 967,859 | $10.4M | 0.00% | +561,296+138.1% | Added |
| Vanguard Capital Management LLC | 833,596 | $8.92M | 0.00% | +2,175+0.3% | Added |
| OrbiMed Advisors LLC | 759,155 | $8.12M | 0.15% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 700,427 | $7.49M | 0.01% | +11,198+1.6% | Added |
| Vanguard Portfolio Management LLC | 652,635 | $6.98M | 0.00% | −29,408−4.3% | Reduced |
| Mackenzie Financial Corp | 628,438 | $6.72M | 0.01% | +475,988+312.2% | Added |
| Madison Avenue Partners, LP | 626,583 | $6.70M | 0.29% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 608,837 | $6.51M | 0.01% | −116,089−16.0% | Reduced |